Michal H.
- Country
- Czechia
- Department
- Plicni klinika
Research Overview
- Phase 3 Study of Pumitamig Versus Pembrolizumab in Previously Untreated Advanced Non-Small Cell Lung Cancer with PD-L1 ≥50%
- Efficacy of Durvalumab and Tremelimumab as Consolidation Therapy in Limited Stage Small-Cell Lung Cancer Post-Concurrent Chemoradiation Therapy
- A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion
Data & Insights
Has run more than one trial at 33 of 188 partner sites.
Specializations
Oncology Focus
This investigator specializes in the treatment of limited stage small-cell lung cancer (LS-SCLC), conducting research into innovative therapeutic approaches for this specific form of lung malignancy.
- Small-cell lung cancer treatment
- Lung cancer therapy development
Their research encompasses patients who have undergone concurrent chemoradiation therapy for LS-SCLC.
Immunotherapy Research
The investigator explores the application of immunotherapy agents in lung cancer treatment, with particular attention to the role of immune checkpoint inhibitors.
- Immune system modulation
- Novel therapeutic combinations
Their work evaluates therapeutic approaches using monotherapy regimens in oncology treatment protocols.
Clinical Outcomes
The investigator focuses on evaluating critical therapeutic outcomes in lung cancer treatment, particularly examining progression-free survival and overall survival metrics.
- Treatment efficacy assessment
- Survival outcomes research
Their research aims to advance understanding of treatment effectiveness in lung cancer therapy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.